Impax Laboratories Inc

Type: Company
Name: Impax Laboratories Inc
Nationality: United States
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Impax Laboratories : Acquires Two Products from Actavis

By a News Reporter-Staff News Editor at Pharma Business Week -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced that it has acquired from Actavis plc (NYSE: ACT) two generic products for cash consideration pursuant to a Purchase Agreement and a Supply ... [Published 4 Traders - Jul 10 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Impax Laboratories : to Announce Results for Second Quarter 2014 on August 6

By a News Reporter-Staff News Editor at Pharma Business Week -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced that the Company will release its second quarter 2014 financial results on Wednesday, August 6, 2014 , prior to the open of the U.S. financial ... [Published 4 Traders - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

6 companies that should report huge earnings gains

AMERICAN VANGUARD CORP. BIG LOTS, Inc. BOISE CASCADE COMPANY CAMBREX CORPORATION DFM BANK IND ENPRO INDUSTRIES GENERAL MOTORS COMPANY GREENHILL & CO., Inc. IMPAX LABORATORIES, Inc. MYERS INDUSTRIES, Inc. Prologis Inc S&P MIDCAP 400 IND STEALTH MINERALS ... [Published Minyanville - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Depomed had the Lowest Relative Performa...

Below are five companies in the Pharmaceuticals industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going ... [Published Financial News Network online - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 2 reports

IMPAX LABORATORIES : Buys 2 Products from Actavis

Impax Laboratories has acquired from Actavis generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement.According to a release, financial terms of the agreement were not disclosed.The acquisition includes one product ... [Published 4 Traders - Jul 08 2014]
First reported Jul 02 2014 - Updated Jul 03 2014 - 6 reports

Impax Laboratories buys two drug tablet programs

Impax Laboratories Inc. bought two generic drugs from Actavis.Hayward-based Impax (NASDAQ: IPXL) paid cash for the two tablet programs — one aimed at cirrhosis, the other at epilepsy — but didn't give a price.Actavis (NYSE: ACT), based in Dublin, Ireland, ... [Published Business First of Buffalo - Jul 03 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 2 reports

Actavis to acquire Forest Lab

Singapore: Actavis has recieved US Federal Trade Commission (FTC) nod to acquire Forest Laboratories following a proposed consent order, pursuant to which the companies have agreed to divest certain products as a condition to obtain FTC approval.Under ... [Published Bio Spectrum Asia - Jul 01 2014]
First reported Jun 30 2014 - Updated Jul 01 2014 - 4 reports

Impax Laboratories to Announce Results for Second Quarter 2014 on August 6

/PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its second quarter 2014 financial results on Wednesday, August 6, 2014, prior to the open of the U.S. financial markets. The Company will host a conference ... [Published BusinessWeek - Jul 01 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Shares of Impax Laboratories Has Risen Above Previous 52-Week High

Written on Wed, 06/25/2014 - 12:27pmBy Amy SchwartzShares of Impax Laboratories ( NASDAQ:IPXL ) traded today at $30.64, breaking its 52-week high. So far today approximately 151,000 shares have been exchanged, as compared to an average 30-day volume ... [Published Comtex SmarTrend - Jun 25 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 2 reports

Patient Enrollments, Innovation Awards, Appointments, and Promotions - Analyst Notes on Endo, St. Jude, Impax, Novavax and PTC Therapeutics

/PRNewswire/ --Today, Analysts Review released its analysts' notes regarding Endo International plc (NASDAQ: ENDP), St. Jude Medical Inc. (NYSE: STJ), Impax Laboratories Inc. (NASDAQ: IPXL), Novavax, Inc. (NYSE: NVAX) and PTC Therapeutics, Inc. (NYSE: ... [Published FinanzNachrichten.de - Jun 25 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 2 reports

Shares of Impax Laboratories Rise to a New 52-Week High

Shares of Impax Laboratories (NASDAQ:IPXL) traded today at $30.49, breaking its 52-week high. So far today approximately 599,000 shares have been exchanged, as compared to an average 30-day volume of 574,000 shares. ... [Published Individual.com - Jun 23 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 2 reports

IGI Laboratories Inc completes seventh ANDA filing for under joint drug development and commercialization agreement with Impax Laboratories, Inc.

1:00pm BST IGI Laboratories Inc:Submits its seventh abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA).Seventh ANDA submission was in connection with an existing development, supply and marketing agreement with ... [Published Reuters UK - Jun 20 2014]

Quotes

...and portfolio with strategic business development projects," said Fred Wilkinson , president and chief executive officer of Impax Laboratories Inc. "Successful implementation of our M&A and business development activities should complement our internal development programs and provide further long term growth for the Company."
Jason Grenfell-Gardner, President and CEO of the Company, commented, "Our team has filed five ANDAs this week alone, including the ANDA we announced earlier today under a partnership with Impax Laboratories Inc.  We set expectations for our team extremely high, and they have proven they can deliver.  We now have seventeen ANDAs pending approval and on file with the FDA, in addition to four more ANDAs pending approval under joint development agreements with our partners.  Our 2014 goal of at least ten ANDA submissions remains on track.  We believe our current pipeline of submissions pending approval by the FDA has a combined addressable market of over $465 million based on recent data from IMS Health."
"Actavis' best-in-class commercial engine is powered by a specialty brand business that is now positioned to compete with the world's leading pharmaceutical companies, marketing more than 35 products across seven therapeutic market segments and maintaining blockbuster product franchises in five therapeutic categories, as well as a global generics business that remains an industry powerhouse, with operations in approximately 60 countries and a top 10 position in more than 25 markets across the world" Saunders said
...Camille Farhat, President of AMS said, "These studies demonstrate the commitment of AMS to provide medical evidence that further validates the safety and efficacy of our products. As a global leader in Women's Health, we will continue to invest in the science that supports these therapies and maintain our support of robust physician training as well as patient education that encourages conversations about the risks and benefits of these treatments." The Company expects that there will be 494 patients enrolled in the Embrace study at approximately 40 sites throughout the United States...

More Content

All (112) | News (73) | Reports (0) | Blogs (33) | Audio/Video (0) | Fact Sheets (0) | Press Releases (6)
sort by: Date | Relevance
Biggest Movers in Healthcare Stocks Now – MNKD ... [Published InvestorPlace.com - Jul 10 2014]
Impax Laboratories : to Announce Results for Se... [Published 4 Traders - Jul 10 2014]
Impax Laboratories : Acquires Two Products from... [Published 4 Traders - Jul 10 2014]
Actavis and Forest Receive U.S. FTC Clearance f... [Published 4 Traders - Jul 09 2014]
Global Anti-Migraine Drugs Market: Trends and O... [Published PR.com Press Releases - Jul 09 2014]
6 companies that should report huge earnings gains [Published Minyanville - Jul 08 2014]
Depomed had the Lowest Relative Performa... [Published Financial News Network online - Jul 08 2014]
IMPAX LABORATORIES : Buys 2 Products from Actavis [Published 4 Traders - Jul 08 2014]
IGI Laboratories, Inc. Announces 18th and 19th ... [Published American Pharmaceutical Outsourcing - Jul 07 2014]
Kosher Certifications, Biologic License Applica... [Published Financial Services - Jul 07 2014]
Impax buys two generic products from Actavis [Published PBR - News - Jul 07 2014]
Impax buys two generic drugs from Actavis [Published BioPortfolio - Jul 05 2014]
Sector Update: Healthcare Stocks Slightly Highe... [Published Nasdaq - Jul 03 2014]
Impax Laboratories buys two drug tablet programs [Published Business First of Buffalo - Jul 03 2014]
Impax Acquires Generic Products from Actavis [Published Zacks.com - Jul 03 2014]
Impax reports purchase of two products from Act... [Published Individual.com - Jul 03 2014]
Impax Labs Acquires Two Generic Products From A... [Published FinanzNachrichten.de - Jul 02 2014]
Impax Labs Acquires Two Generic Products From A... [Published RTTNews.com - Jul 02 2014]
Impax Acquires Two Products from Actavis [Published Barchart - Jul 02 2014]
Impax Acquires Two Products from Actavis [Published PR Newswire: Business Technology - Jul 02 2014]
Following FTC approval, Actavis closes deal on ... [Published Drug Store News - Jul 01 2014]
Actavis completes Forest buy after agreeing wit... [Published FirstWord Pharma - Jul 01 2014]
Impax Laboratories to Announce Results for Seco... [Published BusinessWeek - Jul 01 2014]
US FTC clears Actavis' proposed acquisition of ... [Published PharmaBiz - Jul 01 2014]
Impax Laboratories to Announce Results for Seco... [Published PR Newswire: Health - Jul 01 2014]
Actavis to acquire Forest Lab [Published Bio Spectrum Asia - Jul 01 2014]
Actavis, Forest deal cleared by US regulator af... [Published FirstWord Pharma - Jul 01 2014]
Actavis and Forest Receive U.S. FTC Clearance f... [Published CNBC - Jun 30 2014]
Impax Laboratories Shares Up 13.5% Since SmarTr... [Published Comtex SmarTrend - Jun 30 2014]
Impax Laboratories Shares Up 13.5% Since SmarTr... [Published Individual.com - Jun 30 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Global Anti-Migraine Drugs Market: Trends and O... [Published PR.com Press Releases - Jul 09 2014]
New Delhi, India, July 09, 2014 --( PR.com )-- The report also includes the market value, segmentation, types of diagnosis and treatment for migraine. It also discusses key growth drivers and upcoming trends of the market. Further, key manufacturers ...
Impax buys two generic products from Actavis [Published PBR - News - Jul 07 2014]
Impax Laboratories, Inc. announced that it has acquired from Actavis plc two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. Financial terms of the agreement were not disclosed. ...
Impax Acquires Two Products from Actavis [Published PR Newswire: Business Technology - Jul 02 2014]
HAYWARD, Calif., July 2, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has acquired from Actavis plc (NYSE: ACT) two generic products for cash consideration pursuant to a Purchase Agreement and a Supply Agreement. ...
Impax Laboratories to Announce Results for Seco... [Published PR Newswire: Health - Jul 01 2014]
HAYWARD, Calif., July 1, 2014 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its second quarter 2014 financial results on Wednesday, August 6, 2014, prior to the open of the U.S. financial markets. ...
IGI Laboratories, Inc. Completes Its Seventh AN... [Published PR Newswire: General Business - Jun 20 2014]
BUENA, N.J. and HAYWARD, Calif., June 20, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its seventh abbreviated new drug application (ANDA) in ...
1 2 3 4 5 6 7

Press Releases

sort by: Date | Relevance
Kosher Certifications, Biologic License Applica... [Published Financial Services - Jul 07 2014]
Patient Enrollments, Innovation Awards, Appoint... [Published Financial Services - Jun 25 2014]
Stock Option Programs, Proposed Refinancing, FD... [Published Financial Services - Jun 11 2014]
Morning Coverage of Equities Reaching New Highs... [Published Financial Services - May 05 2014]
Health Care Sector Stocks under Review -- Resea... [Published Financial Services - Apr 08 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.